Orifarm Group completed the acquisition of the OTC and non-core assets of Takeda Pharmaceutical for $670m.

Orifarm Group, a Danish pharmaceutical company, completed the acquisition of the OTC and non-core assets of Takeda Pharmaceutical, a global biopharmaceutical company, for $670m. "These divestments will enable us to further prioritize and reinforce efforts in our core business areas. Throughout the robust sale process we conducted for these assets, we focused on finding the right partner to maximize the value of these trusted products and maintain continuity of supply for the patients and customers who depend on them. We are confident that Orifarm is the right partner for these regions," Giles Platford, Takeda President, Europe & Canada Business Unit.